Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Ricklin

Showing results (81-90 of 135) with videos related to

Pageof 14
Sort By:
Molecular Immunology|November 12, 2010
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potencyHongchang Qu, Paola Magotti, Daniel Ricklin, et al.
Clinical Immunology (Orlando, Fla.)|August 23, 2016
Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemiaMargaret A Lindorfer, Erika M Cook, Edimara S Reis, et al.
Advanced Drug Delivery Reviews|July 21, 2011
Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategiesKristina N Ekdahl, John D Lambris, Hans Elwing, et al.
Thrombosis and Haemostasis|August 22, 2015
Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18Osama A Hamad, Ioannis Mitroulis, Karin Fromell, et al.
The Journal of Biological Chemistry|August 19, 2007
Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureusMichal Hammel, Georgia Sfyroera, Serapion Pyrpassopoulos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2011
Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicineYou-Qiang Wu, Hongchang Qu, Georgia Sfyroera, et al.
Biomaterials|January 28, 2014
Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesiclesYvonne Klapper, Osama A Hamad, Yuji Teramura, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 24, 2025
Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?Nikolaos Paloumpis, Marta Rysz, Noemi Bianchi, et al.
Nature Communications|September 20, 2022
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsChristina Lamers, Xiaoguang Xue, Martin Smieško, et al.
Angewandte Chemie (International Ed. in English)|November 10, 2023
Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell ActivationGabriele Conti, Anne Bärenwaldt, Said Rabbani, et al.
Pageof 14

Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
Molecular Immunology|November 12, 2010
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potencyHongchang Qu, Paola Magotti, Daniel Ricklin, et al.
Clinical Immunology (Orlando, Fla.)|August 23, 2016
Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemiaMargaret A Lindorfer, Erika M Cook, Edimara S Reis, et al.
Advanced Drug Delivery Reviews|July 21, 2011
Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategiesKristina N Ekdahl, John D Lambris, Hans Elwing, et al.
Thrombosis and Haemostasis|August 22, 2015
Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18Osama A Hamad, Ioannis Mitroulis, Karin Fromell, et al.
The Journal of Biological Chemistry|August 19, 2007
Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureusMichal Hammel, Georgia Sfyroera, Serapion Pyrpassopoulos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2011
Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicineYou-Qiang Wu, Hongchang Qu, Georgia Sfyroera, et al.
Biomaterials|January 28, 2014
Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesiclesYvonne Klapper, Osama A Hamad, Yuji Teramura, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 24, 2025
Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?Nikolaos Paloumpis, Marta Rysz, Noemi Bianchi, et al.
Nature Communications|September 20, 2022
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsChristina Lamers, Xiaoguang Xue, Martin Smieško, et al.
Angewandte Chemie (International Ed. in English)|November 10, 2023
Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell ActivationGabriele Conti, Anne Bärenwaldt, Said Rabbani, et al.
Pageof 14